MediLink Therapeutics Announces Strategic Collaboration And Worldwide License Agreement With BioNTech To Develop Next-Gen Anti-Cancer ADCs October 18, 2023
Specialised Therapeutics signs exclusive license agreement with CanariaBio for new ovarian cancer therapy October 18, 2023
Enrollment ex-China in Ph 3 REGAL Trial for Galinpepimut-S in AML Expected to be Completed in Nov 2023 October 18, 2023
Clinical trials of nanrilkefusp alfa as monotherapy and in combinations with pembrolizumab and cetuximab to be discontinued October 18, 2023
Dose Escalation Completed in Ph 1 Trial of INB-100; Enrollment for the Ph 2 Trial of INB-400 in 1L GBM initiated October 18, 2023
